Skip to main content

Akebia Therapeutics, Inc.

AKBA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001517022

In the last 90 days, Akebia Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 170 institutions reported holding it in 13F filings for Q2 2026, worth $123.2M in total; no superinvestor holds it.

13F holders, Q2 2026

Institutional positions in Akebia Therapeutics, Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
170
+1 vs. Q1 2026
Shares held
107.9M
+6.28M (+6.2%) vs. Q1 2026
Total value
$123.2M
−$18.2M (−12.9%) vs. Q1 2026
New holders
37
67 more added
Sold out
36
34 more reduced

2 institutions that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.

Compare with Q1 2026: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting AKBA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ2 2026: 170 institutions
Q1 2021: 145 institutionsQ2 2021: 139 institutionsQ3 2021: 127 institutionsQ4 2021: 133 institutionsQ1 2022: 124 institutionsQ2 2022: 97 institutionsQ3 2022: 90 institutionsQ4 2022: 75 institutionsQ1 2023: 65 institutionsQ2 2023: 79 institutionsQ3 2023: 76 institutionsQ4 2023: 87 institutionsQ1 2024: 114 institutionsQ2 2024: 103 institutionsQ3 2024: 114 institutionsQ4 2024: 121 institutionsQ1 2025: 143 institutionsQ2 2025: 158 institutionsQ3 2025: 177 institutionsQ4 2025: 166 institutionsQ1 2026: 171 institutionsQ2 2026: 170 institutions
Value heldQ2 2026: $123.2M
Q1 2021: $340.3MQ2 2021: $402.4MQ3 2021: $283.7MQ4 2021: $218.7MQ1 2022: $58.3MQ2 2022: $20.2MQ3 2022: $16.5MQ4 2022: $30.2MQ1 2023: $29.1MQ2 2023: $46.0MQ3 2023: $58.0MQ4 2023: $72.7MQ1 2024: $104.3MQ2 2024: $57.4MQ3 2024: $78.4MQ4 2024: $128.9MQ1 2025: $182.7MQ2 2025: $394.1MQ3 2025: $337.7MQ4 2025: $190.4MQ1 2026: $141.4MQ2 2026: $123.2M
Institutions holding AKBA and their total value by quarter
QuarterHoldersValue
Q2 2026170$123.2M
Q1 2026171$141.4M
Q4 2025166$190.4M
Q3 2025177$337.7M
Q2 2025158$394.1M
Q1 2025143$182.7M
Q4 2024121$128.9M
Q3 2024114$78.4M
Q2 2024103$57.4M
Q1 2024114$104.3M
Q4 202387$72.7M
Q3 202376$58.0M
Q2 202379$46.0M
Q1 202365$29.1M
Q4 202275$30.2M
Q3 202290$16.5M
Q2 202297$20.2M
Q1 2022124$58.3M
Q4 2021133$218.7M
Q3 2021127$283.7M
Q2 2021139$402.4M
Q1 2021145$340.3M

Institutions, Q2 2026

Shares, value and share of portfolio for each institution holding Akebia Therapeutics, Inc.; share changes are against Q1 2026.

Institutions holding AKBA in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
GAMMA Investing LLC0$00.00%−382−100.0%Sold out
Northwestern Mutual Wealth Management Co0$00.00%−149−100.0%Sold out
Twin Peaks Wealth Advisors, LLC0$00.00%−24−100.0%Sold out
Hughes Financial Services, LLC0$00.00%−15−100.0%Sold out
Keating Financial Advisory Services, Inc.0$00.00%−10−100.0%Sold out
Nemes Rush Group LLC0$00.00%−2−100.0%Sold out
CWM, LLC––––Not filed
Sunbelt Securities, Inc.––––Not filed